Migalastat is an oral chaperone therapy for patients diagnosed with Fabry disease and who have an amenable variant.1 The mechanism of action of migalastat is presented in Figure 1. The availability of migalastat differs between countries. For further information, please consult your local prescribing information.

Figure 1.
Mechanism of action of migalastat.1,2

C-ANPROM/INT/FAB/0017; Date of preparation: March 2021